CorMatrix Cardiovascular has received US Food and Drug Administration (FDA) 510(k) clearance for its CorMatrix ECM, a device designed for pericardial closure and carotid tissue repair following endarterectomy and suture line buttressing.

CorMatrix ECM uses the company’s proprietary ECM technology, an extracellular matrix biomaterial which provides a natural bio-scaffold, enabling a patient’s own host cells to repopulate and repair damaged tissues.

The unique CorMatrix material helps stimulate tissue growth by providing a location where the patient’s cells can migrate and integrate, eventually creating new tissue in place of the CorMatrix ECM.

The CorMatrix implant is gradually replaced, as the patient’s own body reinforces and rebuilds the weakened site.